fosravuconazole L-lysine ethanolate

08/01/2023 - "The data suggest that F-RVCZ would be effective in various age groups, including the elderly, and even in patients with onychomycosis refractory to long-term topical antifungal treatment. "
10/01/2018 - "The efficacy and safety of F-RVCZ, compared with a placebo, were investigated in a multicenter, double-blind, randomized study of Japanese onychomycosis patients with 25% or more clinical involvement of the target toenail. "
05/01/2021 - "Therefore, we analyzed the outcome of F-RVCZ therapy in the treatment of onychomycosis at outpatient dermatology clinics in Japan. "
01/01/2021 - "This case suggests that F-RVCZ is effective for tinea other than tinea unguium."
01/01/2021 - "A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate."

01/01/2021 - "This case suggests that F-RVCZ is effective for tinea other than tinea unguium."
01/01/2021 - "A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate."

10/01/2018 - "Regarding safety, adverse events were observed in 83.2% (84/101) and 80.8% (42/52), and adverse drug reactions (ADR) in 23.8% (24/101) and 3.8% (2/52) of F-RVCZ and placebo subjects, respectively. "

02/01/2021 - "Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate."

07/01/2020 - "Tinea barbae due to Trichophyton rubrum successfully treated using oral fosravuconazole l-lysine ethanolate."